Chugai Seiyaku Kabushiki Kaisha

Naohiro Yabuta

Hideki Adachi

Koh Sato

Yuji Wakahara

Masayuki Tsuchiya

Hiroyuki Tsunoda

Toshihiko Ohtomo

Kou-ichi Jishage

Tetsuro Orita

Kiyoshi Habu

Kunihiro Hattori

Yasushi Shimonaka

Kou-Ichi Jishage

The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.

Degraded TPO agonist antibody

A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.

Methods of using human tissue factor-producing knock-in mice

Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a method for preparation of the antibody, and uses of the antibody.

Antibodies against human parathyroid hormone related protein

In the case when there are two objective biological activities, and the aim is to isolate a compound having at least one biological activity, the present inventors developed an assay method wherein a common detection marker is utilized for separately detecting the presence or absence of each of the biological activities. The present inventors discovered that a compound having at least one of two or more distinct biological activities can be efficiently and conveniently detected by simultaneously assaying at least one test sample or more by the above-mentioned method. Furthermore, for a test sample that proved to be positive by the detection method, they found that it is possible to efficiently and conveniently screen for a test sample having an objective specific biological activity by combining with a method wherein an individual activity of a test sample can be detected to specify the biological activity.

Screening methods for biologically active ligands

Knock-in non-human animal producing human tissue factor

A humanized antibody against tissue factor (TF), comprising: A: a humanized H chain comprising (1) a H chain V region comprising the H chain CDRs of a mouse monoclonal antibody against TF and the H chain FRs of a human antibody, and (2) the H chain C region of a human antibody; and B: a humanized L chain comprising (1) an L chain V region comprising the L chain CDRs of a mouse monoclonal antibody against TF and the L chain FRs of a human antibody, and (2) the L chain C region of a human antibody. After generating a humanized V region by grafting the CDRs of a mouse monoclonal antibody onto a human antibody, a humanized antibody having a higher activity is searched by replacing the FR of the above region with the corresponding FR of the human antibody having a high homology.

Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody

Antibody against human parathormone related peptides

The present invention relates to a human/mouse chimeric antibody that includes the variable region of a mouse monoclonal antibody against human tissue factor (TF) and the constant region of a human antibody. The humanized antibody contains light and heavy chain complementarity determining regions of a mouse monoclonal antibody against human TF which have been grafted onto a human antibody. The present invention also provides a therapeutic agent for disseminated intravascular coagulation (DIC) syndrome, which includes a humanized antibody against human TF as an active ingredient.

Growing community of inventors

Shizuoka, Japan

Naohiro Yabuta